Skip to main content

Moleculin Biotech, Inc. (MBRX)

NASDAQ: MBRX · IEX Real-Time Price · USD
2.83 0.13 (4.81%)
Oct 21, 2021 1:33 PM EDT - Market open
Market Cap77.72M
Revenue (ttm)n/a
Net Income (ttm)-14.72M
Shares Out28.45M
EPS (ttm)-0.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume222,874
Open2.71
Previous Close2.70
Day's Range2.71 - 2.84
52-Week Range2.61 - 43.92
Beta1.88
AnalystsBuy
Price Target19.00 (+571.4%)
Est. Earnings DateNov 11, 2021

About MBRX

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as...

IndustryBiotechnology
IPO DateJun 2, 2016
Employees10
Stock ExchangeNASDAQ
Ticker SymbolMBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for MBRX stock is "Buy." The 12-month stock price forecast is 19.00, which is an increase of 571.38% from the latest price.

Price Target
$19.00
(571.38% upside)
Analyst Consensus: Buy

News

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phas...

HOUSTON, Oct. 19, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

2 days ago - PRNewsWire

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma L...

HOUSTON, Oct. 18, 2021 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

3 days ago - PRNewsWire

Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference

HOUSTON, Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi...

3 weeks ago - PRNewsWire

Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi...

1 month ago - PRNewsWire

Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

1 month ago - PRNewsWire

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update

HOUSTON, Aug. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

2 months ago - PRNewsWire

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for t...

HOUSTON, July 13, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...

3 months ago - PRNewsWire

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of S...

HOUSTON, June 21, 2021 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti...

4 months ago - PRNewsWire

Moleculin Announces Inclusion in the Russell 2000® Index

HOUSTON, June 15, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targetin...

4 months ago - PRNewsWire

Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients

The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's (NASDAQ: MBRX) Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the company's next-generation anthracycline that h...

4 months ago - Benzinga

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

HOUSTON, May 25, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

4 months ago - PRNewsWire

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

HOUSTON, May 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

5 months ago - PRNewsWire

Moleculin Biotech to Present at the Q2 Virtual Investor Summit

HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

5 months ago - PRNewsWire

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce tha...

5 months ago - GlobeNewsWire

Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor

The FDA has granted Rare Pediatric Disease Designation to Moleculin Biotech Inc's (NASDAQ: MBRX) WP1066 to treat ependymoma. Ependymoma is a rare type of tumor in the brain or spinal cord and most often...

6 months ago - Benzinga

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

HOUSTON, April 14, 2021 /PRNewswire/ --  Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target...

6 months ago - PRNewsWire

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

HOUSTON, April 6, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

6 months ago - PRNewsWire

Moleculin Biotech's Stock Is Trading Higher On Accelerated Review Tag For Annamycin In Connective Tissue Cancer

The FDA has approved Moleculin Biotech Inc's (NASDAQ: MBRX) request for Fast Track Designation for its drug, Annamycin, to treat soft tissue sarcoma (STS) lung metastases. The designation marks the seco...

6 months ago - Benzinga

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

HOUSTON, March 30, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi...

6 months ago - PRNewsWire

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hi...

6 months ago - PRNewsWire

Moleculin to Participate in Four Upcoming Healthcare Conferences

HOUSTON, March 9, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hig...

7 months ago - PRNewsWire

Moleculin Announces Full Exercise of Over-Allotment Option

HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...

8 months ago - PRNewsWire

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma...

HOUSTON, Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

8 months ago - PRNewsWire

Moleculin Announces Proposed Underwritten Public Offering

HOUSTON, Feb. 2, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting ...

8 months ago - PRNewsWire

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

HOUSTON, Feb. 1, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting high...

8 months ago - PRNewsWire